While, to our knowledge, no clinical study in KOA has been designed to target OSM, a new generation of anti‐OSM antibody, GSK2330811, was recently developed and tested in a clinical trial for the treatment of systemic sclerosis (Denton et al., 2022). This evidence concerns the gene OSM and systemic sclerosis.